Abstract
Background: High-altitude pulmonary hypertension (HAPH) is a public health problem in mountainous areas of the world. Treatment options for this condition are unsatisfactory. Recent interest in use of selective phosphodiesterase type 5 (PDE5) inhibitors for pulmonary hypertension has suggested a possible role for these agents in the treatment of HAPH. Preliminary data from several small studies have shown beneficial haemodynamic effects of empirical PDE5 treatment of HAPH but the results of these studies have been challenged.
Objective: We performed a meta-analysis to explore the potential therapeutic effects of PDE5 inhibitors for HAPH. p ]Methods: Randomized controlled trials were identified to test the effects of PDE5 inhibitors in HAPH by searching PubMed (inception to June 2009). A standardized protocol with predefined criteria was used to extract details on study design, Jadad score, demographic data, interventions and outcomes. The main outcomes assessed were cardiopulmonary parameters. Treatment effects for continuous variables were presented as weighted mean differences with 95% confidence intervals.
Results: Ten clinical trials were identified and included for the meta-analysis. The weighted mean difference in systolic pulmonary artery pressure post-treatment at rest in PDE5 inhibitor-treated subjects was −7.51 mmHg (95% CI −10.87, −4.16; p <0.0001) compared with controls, whereas the analysis of systolic blood pressure and heart rate demonstrated that no significant effects were observed in the active treatment group at rest and during exercise.
Conclusions: The available evidence suggests PDE5 inhibitors can attenuate altitude-induced pulmonary hypertension without significantly affecting systemic blood pressure or heart rate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001;345: 107–14
Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol 2005; 98: 390–403
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425–36
Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008; 118: 1195–201
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12
Ghofrani HA, Reichenberger F, Kohstall MG, et al. Silden-afil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004; 141: 169–77
Aldashev AA, Kojonazarov BK, Amatov TA, et al. Phos-phodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005; 60: 683–7
Ricart A, Maristany J, Fort N, et al. Effects of sildenafil on the human response to acute hypoxia and exercise. High Alt Med Biol 2005; 6: 43–9
Cornolo J, Mollard P, Brugniaux JV, et al. Autonomic control of the cardiovascular system during acclimatization to high altitude: effects of sildenafil. J Appl Physiol 2004; 97: 935–40
Richalet JP, Gratadour P, Robach P, et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 2005; 171: 275–81
Hsu AR, Barnholt KE, Grundmann NK, et al. Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. J Appl Physiol 2006; 100:2031–40
Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006; 145: 497–506
Bernheim AM, Kiencke S, Fischler M, et al. Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. Chest 2007; 132: 380–7
Faoro V, Lamotte M, Deboeck G, et al. Effects of sildenafil on exercise capacity in hypoxic normal subjects. High Alt Med Biol 2007; 8: 155–63
Reichenberger F, Kohstall MG, Seeger T, et al. Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. Respir Physiol Neurobiol 2007; 159: 196–201
Kjaergaard J, Snyder EM, Hassager C, et al. Right ventricular function with hypoxic exercise: effects of sildenafil. Eur J Appl Physiol 2007; 102: 87–95
Snyder EM, Olson TP, Johnson BD, et al. Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. Eur J Appl Physiol 2008; 103: 421–30
Lalande S, Snyder EM, Olson TP, et al. The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise. Eur J Appl Physiol 2009; 106: 509–15
Corbin J, Rannels S, Neal D, et al. Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin 2003; 19: 747–52
Guazzi M, Tumminello G, Di Marco F, et al. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004; 44: 2339–48
Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115: 59–66
Acknowledgements
The first two authors contributed equally to this study. The authors gratefully acknowledge Dr Ying Shan for her editorial suggestions for the article. This study was supported in part by the 11th Five-Year National Science Project on Chronic Heart Failure in China (2006BAI01A04). The authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jin, B., Luo, XP., Ni, HC. et al. Phosphodiesterase Type 5 Inhibitors for High-Altitude Pulmonary Hypertension. Clin. Drug Investig. 30, 259–265 (2010). https://doi.org/10.2165/11318360-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11318360-000000000-00000